 CAMBRIDGE, Mass., Nov. 30, 2020 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq:RUBY, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 11:45 a.m. EST. 